Literature DB >> 18000304

Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms.

Susanne Granholm1, Pernilla Lundberg, Ulf H Lerner.   

Abstract

The effects of calcitonin (CT) on osteoclast formation and gene expression have been studied in cultured mouse spleen cells and mouse bone marrow macrophages (BMMs). CT inhibited the formation of multinucleated osteoclasts and resorption pits in spleen cell cultures and BMM as well as in CD115(+) CD3(-) CD45R(-)sorted BMM cultures, incubated in the presence of macrophage colony-stimulating factor and receptor activator of NF-kappaB ligand (RANKL). No effect on apoptosis by CT was observed. CT did not affect the mRNA expressions of RANK and c-Fms, or the mRNA expressions of a wide variety of transcription factors and genes important for osteoclast differentiation and activity. CT induced inhibition of tartrate-resistant acid phosphatase (TRAP), positive multinucleated osteoclast formation was not associated with any decrease of total TRAP activity, resulting in a large number of TRAP(+) mononucleated cells in CT-treated cultures. CT did not affect the mRNA expression of dendritic cell-specific transmembrane protein, d2 isoform of vacuolar (H(+)) ATPase v(o) domain, a disintegrin and metalloproteinase domain 8 (ADAM8), ADAM12, DNAX-activating protein or Fc receptor common gamma chain suggested to be involved in fusion of mononucleated osteoclast progenitor cells. The inhibitory effect by CT was mimicked not only by compounds activating cAMP and protein kinase A (PKA) but also by a cAMP analogue activating the exchange protein directly activated by cAMP (Epac) pathway. It is concluded that CT, through cAMP/PKA/Epac cascades, inhibits osteoclast formation and that this effect is not associated with decreased transcription of genes known to be important for osteoclast progenitor cell differentiation, fusion or function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000304     DOI: 10.1677/JOE-07-0338

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  21 in total

1.  Activation of EPAC1/2 is essential for osteoclast formation by modulating NFκB nuclear translocation and actin cytoskeleton rearrangements.

Authors:  Aránzazu Mediero; Miguel Perez-Aso; Bruce N Cronstein
Journal:  FASEB J       Date:  2014-08-13       Impact factor: 5.191

Review 2.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

3.  Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function.

Authors:  Firas M Kara; Violeta Chitu; Jennifer Sloane; Matthew Axelrod; Bertil B Fredholm; E Richard Stanley; Bruce N Cronstein
Journal:  FASEB J       Date:  2010-02-24       Impact factor: 5.191

4.  Simvastatin-doped pre-mixed calcium phosphate cement inhibits osteoclast differentiation and resorption.

Authors:  M Montazerolghaem; A Rasmusson; H Melhus; H Engqvist; M Karlsson Ott
Journal:  J Mater Sci Mater Med       Date:  2016-03-11       Impact factor: 3.896

5.  Proton concentrations can be a major contributor to the modification of osteoclast and osteoblast differentiation, working independently of extracellular bicarbonate ions.

Authors:  Kohtaro Kato; Misao Matsushita
Journal:  J Bone Miner Metab       Date:  2013-07-16       Impact factor: 2.626

6.  Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism.

Authors:  Kirsten M Robertson Remen; Petra Henning; Ulf H Lerner; Jan-Åke Gustafsson; Göran Andersson
Journal:  J Biol Chem       Date:  2011-07-22       Impact factor: 5.157

7.  Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts.

Authors:  Yukiko Kuroda; Koichi Matsuo
Journal:  World J Orthop       Date:  2012-11-18

8.  Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures.

Authors:  Sofia Movérare-Skrtic; Petra Henning; Xianwen Liu; Kenichi Nagano; Hiroaki Saito; Anna E Börjesson; Klara Sjögren; Sara H Windahl; Helen Farman; Bert Kindlund; Cecilia Engdahl; Antti Koskela; Fu-Ping Zhang; Emma E Eriksson; Farasat Zaman; Ann Hammarstedt; Hanna Isaksson; Marta Bally; Ali Kassem; Catharina Lindholm; Olof Sandberg; Per Aspenberg; Lars Sävendahl; Jian Q Feng; Jan Tuckermann; Juha Tuukkanen; Matti Poutanen; Roland Baron; Ulf H Lerner; Francesca Gori; Claes Ohlsson
Journal:  Nat Med       Date:  2014-10-12       Impact factor: 53.440

9.  Calcitonin receptor-mediated CFTR activation in human intestinal epithelial cells.

Authors:  Hongguang Liu; Amika Singla; Mei Ao; Ravinder K Gill; Jayashree Venkatasubramanian; Mrinalini C Rao; Waddah A Alrefai; Pradeep K Dudeja
Journal:  J Cell Mol Med       Date:  2011-12       Impact factor: 5.310

10.  The 18 kDa translocator protein (peripheral benzodiazepine receptor) expression in the bone of normal, osteoprotegerin or low calcium diet treated mice.

Authors:  Winnie Wai-Ying Kam; Steven R Meikle; Hong Zhou; Yu Zheng; Julie M Blair; Marcus Seibel; Colin R Dunstan; Richard B Banati
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.